CN115461372A - 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 - Google Patents

一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 Download PDF

Info

Publication number
CN115461372A
CN115461372A CN202180031534.9A CN202180031534A CN115461372A CN 115461372 A CN115461372 A CN 115461372A CN 202180031534 A CN202180031534 A CN 202180031534A CN 115461372 A CN115461372 A CN 115461372A
Authority
CN
China
Prior art keywords
seq
antibody
human
bispecific antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031534.9A
Other languages
English (en)
Inventor
屈向东
潘琴
金后聪
郑翰
都业杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiyu Biotechnology Shanghai Co ltd
Original Assignee
Qiyu Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiyu Biotechnology Shanghai Co ltd filed Critical Qiyu Biotechnology Shanghai Co ltd
Publication of CN115461372A publication Critical patent/CN115461372A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种靶向人claudin和人PDL1蛋白的双特异抗体，其特征在于，包括：抗人claudin18.2的抗体部分和抗PD‑L1抗体部分。该双特异性抗体在结合人claudin18.2蛋白的同时，也可以阻断PD‑1/PD‑L1的结合，既能在先天性免疫中起到激活NK细胞杀伤肿瘤细胞，又能在获得性免疫重起到促进杀伤性T淋巴细胞对肿瘤的杀伤作用。该双特异性抗体比单独使用抗claudin18.2抗体具有更好的抗肿瘤疗效。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202180031534.9A 2020-04-27 2021-04-25 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 Pending CN115461372A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010344676.8A CN113637082A (zh) 2020-04-27 2020-04-27 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN2020103446768 2020-04-27
PCT/CN2021/089729 WO2021218874A1 (zh) 2020-04-27 2021-04-25 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用

Publications (1)

Publication Number Publication Date
CN115461372A true CN115461372A (zh) 2022-12-09

Family

ID=78331761

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010344676.8A Pending CN113637082A (zh) 2020-04-27 2020-04-27 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN202180031534.9A Pending CN115461372A (zh) 2020-04-27 2021-04-25 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010344676.8A Pending CN113637082A (zh) 2020-04-27 2020-04-27 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用

Country Status (6)

Country Link
US (1) US20230183352A1 (zh)
EP (1) EP4144759A4 (zh)
JP (1) JP7463000B2 (zh)
KR (1) KR20230005276A (zh)
CN (2) CN113637082A (zh)
WO (1) WO2021218874A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327182A (zh) * 2023-09-19 2024-01-02 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116410326A (zh) * 2021-12-30 2023-07-11 三优生物医药(上海)有限公司 抗cd40×cldn18.2双特异性抗体及其用途
TW202400662A (zh) * 2022-05-17 2024-01-01 大陸商蘇州創勝醫藥集團有限公司 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途
CN117164719A (zh) * 2022-05-28 2023-12-05 启愈生物技术(上海)有限公司 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
SG10202111141WA (en) * 2018-05-18 2021-11-29 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
US11912763B2 (en) 2018-06-17 2024-02-27 L & L Biopharma Co., Ltd. Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
CN110606891B (zh) * 2018-06-17 2022-12-06 上海健信生物医药科技有限公司 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途
EP3826612A4 (en) 2018-07-25 2022-09-14 Accurus Biosciences, Inc. NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
CN110885377B (zh) * 2018-09-11 2020-12-04 上海洛启生物医药技术有限公司 抗cd47/vegf双特异性抗体及其应用
CN110885376B (zh) * 2018-09-11 2020-10-09 上海洛启生物医药技术有限公司 抗cd47/cd20双特异性抗体及其用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN111944048B (zh) * 2019-05-16 2023-10-03 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
CN112142842B (zh) * 2019-06-27 2023-09-01 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327182A (zh) * 2023-09-19 2024-01-02 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用

Also Published As

Publication number Publication date
EP4144759A4 (en) 2024-05-29
CN113637082A (zh) 2021-11-12
EP4144759A1 (en) 2023-03-08
JP2023522492A (ja) 2023-05-30
KR20230005276A (ko) 2023-01-09
WO2021218874A1 (zh) 2021-11-04
JP7463000B2 (ja) 2024-04-08
US20230183352A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7264827B2 (ja) ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途
JP6779299B2 (ja) 抗ｐｄ−ｌ１抗体およびその使用
KR102469286B1 (ko) 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도
US20220002418A1 (en) Anti-pd-l1/vegf bifunctional antibody and use thereof
CN115461372A (zh) 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
KR20120060235A (ko) 특이성 결합 단백질 및 용도
CN111995685B (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
EP4112647A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
CN114761433A (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
WO2022188801A1 (zh) Pd-1结合蛋白及其医药用途
CN114057883A (zh) 双特异性抗原结合分子及其医药用途
JP2022517216A (ja) 組換え抗ヒトｐｄ－１抗体およびその用途
US20230374132A1 (en) Anti-cd3 antibody and uses thereof
CN114573704B (zh) Pd-1/ctla-4结合蛋白及其医药用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
WO2023040945A1 (zh) 特异性结合pd-1的蛋白及其医药用途
WO2022117003A1 (zh) 抗PD-L1/TGF-β双功能抗体及其用途
TW202305007A (zh) 靶向pd-l1和cd73的特異性結合蛋白
CN116284427A (zh) 抗muc17/cd3双特异性抗体、其制备方法及用途
TW202305011A (zh) 靶向ｐｄ－１和／或ｏｘ４０的特異性結合蛋白
CN117126289A (zh) 一种抗trop-2/cd3双特异性抗体
CN112867733A (zh) 抗cd137抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination